Category: by subject

Does a new retraction suggest a glimmer of hope for transparency at the Journal of Neuroscience?

Believe it or not, we look for policies to praise here at Retraction Watch HQ, especially if they mark a change from approaches that we and others have criticized. So we were heartened to read this retraction notice in The Journal of Neuroscience for “Lmx1b-Controlled Isthmic Organizer Is Essential for Development of Midbrain Dopaminergic Neurons:”

The Journal of Neuroscience has received a report describing an investigation by the Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, which found major data misrepresentation in the article by Guo et al. Because the results cannot be considered reliable, The Journal is retracting the paper.

The study has been cited five times since it was published in 2008, according to Thomson Scientific’s Web of Knowledge. Here’s some background on why we thought we’d have something to praise, from a Nature feature this week on retractions: Continue reading Does a new retraction suggest a glimmer of hope for transparency at the Journal of Neuroscience?

Do editors like talking about journals’ mistakes? Nature takes on retractions

courtesy Nature

One of the themes we’ve hit hard here at Retraction Watch is that there is tremendous variation in how journals deal with retractions. Some make notices crystal clear, while others seem to want to make them as opaque as possible. Some editors go out of their way to publicize withdrawals, while others bury them and won’t talk about them when they appear. 

In a Nature feature out today on retractions, Richard van Noorden highlights those disparities. He also highlights the fact that there are more retractions to talk about: As a graphic accompanying the piece makes clear, retractions have risen 10-fold in the last decade, even as the number of papers published has grown by less than fifty percent.

But even with that growth, the number of retractions — we’re on track for 400 this year, according to Thomson Reuters — is a vanishingly small percentage of the 700,000 papers published annually. Still, science prides itself on transparency — or should, anyway. van Noorden gives Ivan the chance to offer some advice to those scientists and editors who are reluctant to acknowledge there’s ever any dirty laundry in science: Continue reading Do editors like talking about journals’ mistakes? Nature takes on retractions

Nursing researcher Scott Weber draws penalties from ORI in plagiarism, fraud scandal

Scott Weber, the nursing researcher whose publishing misconduct has cost him posts at the University of Pittsburgh and Walden University, has been sanctioned by the Office of Research Integrity for his misdeeds.

According to a link posted today on the ORI website: Continue reading Nursing researcher Scott Weber draws penalties from ORI in plagiarism, fraud scandal

“Ill communication” leads to retraction of tissue paper (sorry) for authorship issues

Like many researchers, Frank Walboomers frequently checks the scientific databases to see when his latest publications appear. He was doing so a few months ago when he came across his name on an article — “Effects of pro-inflammatory cytokines on mineralization potential of rat dental pulp stem cells” — published online in July in the Journal of Tissue Engineering and Regenerative Medicine, that he hadn’t written.

The first author of the paper, Xuechao Yang, was a former doctoral student in Walboomers’ laboratory at Radboud University Nijmegen. It didn’t take Walboomers long to figure out what had happened: Continue reading “Ill communication” leads to retraction of tissue paper (sorry) for authorship issues

New in PNAS: Potti retraction number seven, and a Potti correction

The Proceedings of the National Academy of Sciences (PNAS) has published the seventh retraction for former Duke researcher Anil Potti, who now faces a lawsuit in the midst of an ongoing investigation into his work:

Retraction for “A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities,” by Katherine S. Garman, Chaitanya R. Acharya, Elena Edelman, Marian Grade, Jochen Gaedcke, Shivani Sud, William Barry, Anna Mae Diehl, Dawn Provenzale, Geoffrey S. Ginsburg, B. Michael Ghadimi, Thomas Ried, Joseph R. Nevins, Sayan Mukherjee, David Hsu, and Anil Potti, which appeared in issue 49, December 9, 2008, of Proc Natl Acad Sci USA (105:19432–19437; first published December 2, 2008; 10.1073/pnas.0806674105).

The authors wish to note the following: “We wish to retract this article because we have been unable to reproduce certain key experiments described in the paper regarding validation and use of the colon cancer prognostic signature. This includes the validation performed with dataset E-MEXP-1224, as reported in Fig. 2A, as well as the generation of prognostic scores for colon cancer cell lines, as reported in Fig. 4. Because these results are fundamental to the conclusions of the paper, the authors formally retract the paper. We deeply regret the impact of this action on the work of other investigators.”

The 2008 paper, which has been cited 27 times, according to Thomson Scientific’s Web of Knowledge, was already the subject of a minor 2009 correction: Continue reading New in PNAS: Potti retraction number seven, and a Potti correction

Authors retract chemistry paper after failing to get company’s permission to publish

Two chemists who published a paper earlier this year in Bioconjugate Chemistry have withdrawn it, after their company, Life Technologies, let them know they didn’t have permission to submit the work. The retraction notice reads:

Facile Synthesis of Symmetric, Monofunctional Cyanine Dyes for Imaging Applications, by Lai-Qiang Ying and Bruce P. Branchaud, Bioconjugate Chem., 2011, 22 (5), pp 865–869, DOI: 10.1021/bc2001006, has been retracted at the request of the authors and Life Technologies. The article was submitted for publication without the approval of Life Technologies.

Where the paper had appeared previously — it’s been completely removed from the journal’s site, as opposed to being marked as “withdrawn” or “retracted” — this is all that’s left: Continue reading Authors retract chemistry paper after failing to get company’s permission to publish

Physics paper in Science retracted after Vanderbilt facility closes

If the facility you need to reproduce your experiments closes after you’ve discovered questions about your original findings, what do you do?

If you’re a group of physicists that published a 2006 paper in Science, “Desorption of H from Si(111) by Resonant Excitation of the Si-H Vibrational Stretch Mode,” you retract your study. Here’s the notice, from today’s Science: Continue reading Physics paper in Science retracted after Vanderbilt facility closes

You can do that? A massive correction in Nature, but no retraction

courtesy Nature

This past April, Amparo Acker-Palmer and colleagues published a study in Nature, “Ephrin Bs are essential components of the Reelin pathway to regulate neuronal migration.” Within a day of its publication, Nature readers were raising questions about many of its figures. They started like this:

Andy Gu said:

Looks like Fig 1a, the two middle figures are actually the same with little move from desired regions. I don’t trust their data now…..

After several such comments, Nature senior editor Noah Gray weighed in: Continue reading You can do that? A massive correction in Nature, but no retraction

Lack of ethical approval leads to JCO retraction

The Retraction Watch category for “lack of IRB approval” as a reason for retraction — a subject we covered in our most recent Lab Times column — is growing. First there were the 90-odd retractions by Joachim Boldt, then three by Australian researchers studying Aussie-rules football players. Now, we learn that the Journal of Clinical Oncology has retracted a paper over concerns that the authors failed to obtain ethical approval to conduct their study.

The 2010 publication, by researchers at Saitama Medical University in Japan, reported on an analysis of 314 lymphoma patients being treated with chemotherapy — some, and perhaps none, of whom knew they were being studied.

Here’s the notice, which appeared this month: Continue reading Lack of ethical approval leads to JCO retraction

More on Hattori case from co-author: Did grudge lead to scientist’s fall?

We have an update on the case of Yoshiyuki Hattori, the Japanese endocrinologist who has had a half-dozen papers retracted because of issues involving reused data. We’ve reported on some of those retractions, and report on three new ones here.

As a trainee, Hattori spent some time in England, where he met Steven Gross, a prominent pharmacology researcher at Cornell. Gross was impressed with the young physician-scientist, and invited him back to his New York City laboratory to do a postdoc.

Gross’ name appears on one of the retracted articles, “NO suppresses while peroxynitrite sustains NF-κB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO,” which appeared in 2004 in the journal Cardiovascular Research and has been cited 42 times, according to Thomson Scientific’s Web of Knowledge.

According to the notice: Continue reading More on Hattori case from co-author: Did grudge lead to scientist’s fall?